Day: November 7, 2025

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – Vancouver, B.C., Nov. 07, 2025 (GLOBE NEWSWIRE) — NextGen Digital Platforms Inc. (CSE:NXT) (OTCQB:NXTDF) (FSE:Z12) (“NextGen” or the “Company”) announces, further to its news release of October 6, 2025, that the Company has completed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement of units (the “Offering”). Pursuant to the First Tranche, the Company issued 2,065,000 units of the Company (the “Units”) at $0.40 per Unit for gross proceeds of $826,000. Each Unit will consist of one common share in the capital of the Company (a “Share”) and one half of a transferrable common share purchase warrant (a “Warrant”).  Each whole Warrant will entitle the holder to purchase one additional Share at a price of...

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 (p

EL SEGUNDO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — As previously announced, Beyond Meat, Inc. (NASDAQ: BYND) (“Beyond Meat” or “the Company”), a leader in plant-based meat, will host its conference call to discuss its financial results for the third quarter ended September 27, 2025 on Tuesday, November 11, 2025 at 5:00 p.m. Eastern, 2:00 p.m. Pacific. However, the Company announced today that it will now report its financial results for the third quarter ended September 27, 2025 on Monday, November 10, 2025, one day earlier than previously indicated. The adjustment has been made in recognition of the Veterans Day holiday, during which the U.S. Securities and Exchange Commission (“SEC”) will be closed. As previously announced, investors interested in participating in the live call on Tuesday, November 11, 2025 can dial 412-902-4255. There...

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO XR Most (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their mental health condition remained stable or improved Teva is committed to truly understanding and empowering individuals living with TD to help improve their TD and regain their independencePARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new data from the ongoing, real-world IMPACT-TD Registry. The findings demonstrate that treatment with AUSTEDO...

GUADALAJARA, Mexico, Nov. 07, 2025 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for October 2025, compared with October 2024. During this period, the total number of terminal passengers at GAP’s 12 Mexican airports increased by 0.7%, compared to October 2024. Guadalajara and Puerto Vallarta airports presented an increase in passenger traffic of 2.1% and 1.7%, respectively, while Tijuana, and Los Cabos airports decreased 4.2%, and 2.1%, respectively. Regarding Jamaica’s airports, Montego Bay Airport decreased by 17.6%, while Kingston declined by 13.0%, due to the impacts of Hurricane Melissa.Domestic Terminal Passengers (in thousands):             Airport Oct-24 Oct-25 % Change Jan – Oct...

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session – RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company developing therapies to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that clinical data for lorundrostat were presented at the American Society of Nephrology (ASN) Kidney Week 2025. Findings included a late-breaking oral presentation of the Phase 2 Explore-CKD trial and recognition of the pivotal Phase 3 Launch-HTN trial in the “Best of the Journal of the American Medical Association (JAMA) and the New...

Vancouver, BC, Nov. 07, 2025 (GLOBE NEWSWIRE) — Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) announces that it has granted an aggregate 831,356 restricted share units (“RSUs”) and 20,964 stock options (“Options”) to consultants and employees of the Company and its subsidiary, Rocket Doctor Inc. The Options are each exercisable for one common share of the Company at an exercise price of C$0.82 per share for a period of three years from the grant date and subject to vesting provisions. 325,000 RSUs are valid for a term of two years and 506,356 RSUs are valid for a term of three years. 203,000 RSUs vest immediately and 628,356 are subject to vesting provisions.  All Options and RSUs are subject to the terms of the Company’s equity plans and applicable securities law hold periods. About Rocket...

TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Summit Royalties Ltd. (TSXV: SUM) (the “Corporation” or “Summit Royalties“) is pleased to announce corporate updates in connection with the recently completed go-public transaction by way of a reverse takeover (the “RTO“). Commencement of Trading on the TSX Venture Exchange In connection with the closing of the RTO and further to its news release on November 5, 2025 (titled “Summit Royalties Completes Go-Public Transaction”), the common shares of the Corporation (the “Common Shares“) are scheduled to commence trading on the TSX Venture Exchange (the “Exchange“) at market open on Monday, November 10, 2025, under the symbol “SUM”. In anticipation of commencement of trading on the Exchange, the Common Shares...

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01’s already strong data packageCOPENHAGEN, Denmark, November 7, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment with AI-designed personalized cancer vaccine EVX-01. The data was presented today in a poster session at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting taking place in National Harbor, Maryland. Developed with Evaxion’s AI-Immunology™ platform, EVX-01 is designed to target multiple...